NDA Partners LLC: A Development Partner to Biopharmaceutical Investors and Companies

Michael A. Eldon, PhD, FCP

Practice Area Focus

  • Drugs
  • Devices
  • Combination Products
  • PKPD
  • Pharmacometrics
  • Translational Science
  • Clinical Study Design
  • Development Strategy
  • Regulatory Strategy
  • Regulatory Submissions


Dr. Eldon joined NDA Partners as an Expert Consultant in 2017. Dr. Eldon has more than 35 years of experience in clinical pharmacology, pharmacokinetics/pharmaco-dynamics and pharmacometrics in the pharmaceutical industry.

As Vice President of Clinical Pharmacology at Nektar Therapeutics and a member of Nektar’s corporate-level Research and Clinical Development Committees, Dr. Eldon was responsible for clinical and preclinical pharmacokinetics, ADME, pharmacometrics and systems biology in drug development and discovery.

Prior to Nektar, Dr. Eldon worked at Parke-Davis Pharmaceutical Research where he participated in the development and registration of Lipitor (atorvastatin), Neurontin (gabapentin), Rezulin (troglitazone), Lyrica (pregabalin), Pro-Air (procaterol), Lopid (gemfibrozil), Loestrin (oral contraceptive), Estrostep (oral contraceptive), Procanbid (procainamide extended release), FemPatch (transdermal estradiol), Cerebyx (fosphenytoin), Penetrex (enoxacin), Zagam (sparfloxacin) and Nitrostat (nitroglycerin) stabilized tablets. While at Nektar, he participated in the discovery, development and registration of Movantik and Exubera (rH insulin for inhalation); and the discovery and preclinical and clinical development of other Nektar proprietary products including Onzeald (etirinotecan pegol), NKTR-181, and NKTR-214.